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Abstract
Unlike their protein “roommates” and their nucleic acid “cousins,” carbohydrates remain an
enigmatic arm of biology. The central reason for the difficulty in fully understanding how
carbohydrate structure and biological function are tied is the nontemplate nature of their synthesis
and the resulting heterogeneity. The goal of this collection of expert reviews is to highlight what is
known about how carbohydrates and their binding partners—the microbial (non-self), tumor
(altered-self), and host (self)—cooperate within the immune system, while also identifying areas
of opportunity to those willing to take up the challenge of understanding more about how
carbohydrates influence immune responses. In the end, these reviews will serve as specific
examples of how carbohydrates are as integral to biology as are proteins, nucleic acids, and lipids.
Here, we attempt to summarize general concepts on glycans and glycan-binding proteins (mainly
C-type lectins, siglecs, and galectins) and their contributions to the biology of immune responses
in physiologic and pathologic settings.
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Glycobiology—an overview
Calling nucleic acids “cousins” of carbohydrates is an accurate representation of the fact that
both DNA and RNA are essentially polysaccharides composed of phosphate-linked
polyribose cores. Without carbohydrates, nucleic acids would not form the linear scaffolding
required for their function. Likewise, proteins and carbohydrates can be termed
“roommates” because, in mammals, carbohydrates are nearly always associated with either
proteins or lipids. With some notable exceptions (e.g., β2-microglobulin and the galectin
family), all secreted proteins and all cell surface proteins and lipids contain significant
amounts of covalently attached glycans. In some cases the molecular mass of a glycoprotein
can be as much as 50% carbohydrate or more,1 with the carbohydrates falling into two
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categories, N-linked or O-linked (Fig. 1), depending on the nature of the linkage to the
underlying protein backbone.2,3 Molecular pathways required for N- and O-linked
carbohydrate pathways, or at least primitive versions of them, are also present in the
microbial world, with the most remarkable example being Campylobacter species that can
add both O- and N-linked carbohydrates to their proteins (e.g., flagellin).4 Importantly in
humans, loss of genes in these pathways (conditions known as congenital disorders of
glycosylation) is often embryonically lethal; but when individuals survive, the pathologies
present are typically quite devastating.5–7 Remarkably, the mammalian glycome repertoire is
estimated to include thousands of glycan structures generated by the concerted action of an
endogenous group of glycosyltransferases and glycosidases.8
The general physiologic roles of carbohydrates and their binding partners are highly diverse
and include critical functions in cell–cell communication and adhesion,9 protein structural
stability,10 membrane structure,11 and cellular signaling.12 Indeed, while carbohydrates play
as varied roles in biology as proteins do, they have been problematic to study due to the
inherent differences between the complex synthetic pathways for carbohydrates and the
template-driven synthesis of nucleic acids and proteins, and this has unfortunately led many
investigators to ignore the “complicating factor” that carbohydrates can seem to represent.
One particularly stark example is the understanding of protein structure and function, much
of which depends on the decades of crystallography that have created a cache of structural
information with which we interpret key functional data. Protein crystallography depends on
well-ordered crystals forming. But the typical mammalian pattern of glycosylation often
precludes the formation of high-quality crystals. As a result, the approaches to determining
the three-dimensional structure of a glycoprotein include recombinant overexpression in E.
coli to prevent the addition of glycans completely13 and expression in Sf9 insect cells,14
which produces proteins that carry only limited mannose structures that resemble the hybrid
N-glycan structures shown in Figure 1 and are more homogeneous than the mammalian
counterparts.15 At the same time, a wealth of data have shown that fully complex-type
glycans characteristic of mammalian glycoproteins are required for native function. One can
immediately recognize the problem with assigning a single structure or function—or a list of
binding partners—to a glycoprotein when the protein used in the experiments lacks the
native glycosylation patterns found in vivo. As of 2011, the reality is that our structural
knowledge of how carbohydrates—integral components of proteins—(possibly as many as
80–90% of all human proteins are glycosylated) may affect function remains in its infancy.
Another point worth making is the issue of heterogeneity, the central complicating aspect of
glycobiology. Complex-type N-glycans, for example, are hallmarks of mammalian
glycoproteins, and as one moves down the evolutionary ladder protein glycosylation
becomes simpler despite the genetic similarities among organisms. As such, it seems
entirely reasonable to suggest that the inherent heterogeneity associated with these pathways
is integral to their function in biology. The reductionist in each of us wants our experiments
to be as clean as possible by limiting the variables, but perhaps it is the very molecular
heterogeneity that we try to avoid in experiments that is the key to unlocking our
understanding life and the differences among species and differences associated with
disease. If correct, it is impossible to study systems biology in the absence of understanding
and investigating the contributions of glycobiology and the underlying carbohydrate
heterogeneity to biological processes.
Although one can paint a relatively bleak picture of our ability to dissect the global
complexities of carbohydrate biological function, the last decade has seen some remarkable
progress in terms of the creation of tools to determine glycan structure and diversity, as well
as in the collaborative efforts to pool expertise in tackling the “glycomics problem.” Under
the leadership of James Paulson at the Scripps Research Institute, the Consortium for
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Functional Glycomics (CFG) was created and funded by the National Institute of General
Medical Sciences. Although the ten years of funding is now complete, the CFG was
responsible for the creation and development of numerous tools to assist investigators with
understanding the role of carbohydrates in a variety of biological systems. One particularly
important resource is the glycan-binding array in which hundreds of carbohydrates
representing a wide variety of structures were covalently attached to a chip for binding
studies.16 Another key resource created by the CFG is a gene chip including genes that
encode all carbohydrate-associated proteins and pathway enzymes, which enables studies on
the regulation of glycosylation and other mechanisms as a function of disease state.17 The
collective efforts represented by the CFG and other worldwide efforts, such as EuroCarb and
the Japanese Consortium for Glycobiology and Glycotechnology, the world of glycomics
has begun to open to the nonspecialist and will likely lead to rapid progress in understanding
the multifaceted roles of carbohydrates in physiology.
Glycans and the immune system—an introduction
The focus of this issue of Annals of the New York Academy of Sciences is one part of the
overall picture of carbohydrate structure and function: the immune system. The immune
response is an ideal system in which to begin painting a larger picture of carbohydrates and
their role in biology, because of the importance of glycans and their binding partners in
nearly every aspect of immunology (Fig. 2).
As with all cells, essentially all surface-localized immune receptors are glycoproteins,
including pattern recognition receptors (PRRs) such as toll-like (TLR) and NOD-like
receptors, the class I and class II major histocompatibility complex proteins (MHC class I
and MHC class II), chemokine receptors, cytokine receptors, T and B cell coreceptors, and
the T and B cell receptors themselves. The role of the glycans on these molecules is as
varied as the molecules themselves. For example, prevention of complex-type N-glycan
synthesis on T cells substantially increases T cell receptor signaling, making T cell
activation much less stringent.18 In addition, the loss of complex-type N-glycans on MHC II
significantly impedes the ability to present bacterial polysaccharides to T cells,19 whereas
mutagenesis of TLR molecules to remove sites of glycosylation directly influences their
signaling.20,21
Other components of the immune system are the various glycan-binding proteins (GBPs) or
lectins, including the C-type lectins, siglecs, and galectins. Through binding to lectins and
sterically modulating molecular interactions, mammalian glycans participate in a diversity of
cellular mechanisms that contribute to innate and adaptive immune responses.8 The theme
with these molecules is that they are carbohydrate-binding molecules, and they also tend to
be glycoproteins, with the exception of the galectin family. One well-known family member
is DC-SIGN, a C-type lectin receptor (CLR) found on the surface of dendritic cells (DCs)
that serves to bind a variety of mannose- and fucose-containing ligands, including
glycoproteins of the envelope of human immunodeficiency virus (HIV), and signals into the
cell for activation.22 Another example is CD22, a member of the siglec (sialic acid–binding
Ig-like lectin) family and a crucial part of the B cell receptor complex that assists with
antigen uptake and B cell activation.23,24 Finally, the galectins are thought to be able to
associate with host glycans, such that the cell surface can be organized into receptor lattices
for optimal receptor spacing and signaling.11,25
Secreted glycoproteins in the immune system include essentially all cytokines and
chemokines, many of the complement components, and antibodies. One recent and
important discovery is that the N-glycans attached to the Fc portion of IgG molecules
modulate antibody activity,26,27 for example, antibodies’ terminal sialic acids send an
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inhibitory signal to responding immune cells, whereas those missing terminal sialic acids
send activating signals. Another pathway to note is the lectin pathway for complement
activation, which requires the mannose-binding lectin and ficolins, rather than the classical
components such as C1q.28
Two other areas of note are lymphocyte development and leukocyte homing. The Notch
family of molecules relies upon glycan changes, especially the addition of fucose residues,
to mediate T and B cell differentiation into the various known lineages from common
progenitors.29 For homing, migrating cells rely upon the selectin family of adhesion
molecules on circulating leukocytes; the selectins bind to specific carbohydrates expressed
on the surface of endothelial cells near sites of inflammation and infection.30,31 This enables
the cells to home to sites where they are needed.
Turning to microbes, a majority of their immunogens are glycans or glycan conjugates, and
nearly all bacteria and viruses are coated with a thick glycocalyx (sugar coat). For HIV, its
often-cited gp120 coat protein is glycosylated to the point that most of the underlying
protein is inaccessible to antibodies.32 Some bacteria are completely encapsulated with
polysaccharides,33 whereas others have thick coats of endotoxin and other glycolipids.
Gram-positive bacteria also have externally exposed peptidoglycans. From these groups,
essentially all of the so-called pathogen-associated molecular patterns can be found (e.g.,
endotoxin/LPS, viral coats, muramyl dipeptide, and bacterial capsules). An important point
is that many pathogens have evolved to make host-like carbohydrates at their cell surface to
mimic the host and evade immune detection.34 This fact alone shows the importance of
carbohydrate immunogens, because if the immune system did not recognize carbohydrates
specifically, there would be no need to be tolerant of self-carbohydrates, and pathogens
would not be able to hide through mimicry.
Although the diversity of glycans and GBPs, coupled with the diversity of pathways
involved in shaping and directing the immune response, is as broad as immunology itself,
this issue touches on several key topics under active investigation around the world. These
areas are described below and further elaborated on in the papers collected in this special
issue.a
GBPs in self, non-self, and altered-self recognition
Several GBPs are expressed on cells of the immune system and/or released to the
extracellular milieu where they play essential roles in the control of innate and adaptive
immunity.35 These include the families of CLRs, siglecs, and galectins that mainly function
through recognition of defined carbohydrate structures decorating glycoproteins or
glycolipids.35 All these GBPs carry one or more carbohydrate recognition domains (CRD)
that coordinate the interaction with a specific glycan. CLRs are calcium-dependent
carbohydrate binding proteins, where specific amino acids in the CRD coordinate the
carbohydrate ligand and a Ca2+ ion.36 C-type lectins that contain an Glu–Pro–Asn (EPN)
amino acid motif, such as DC-SIGN, mannose receptor (MR), Langerin, and L-SIGN/DC-
SIGNR,37 have specificity for mannose- and/or fucose-terminated glycans. In contrast,
galactose-specific C-type lectins like macrophage galactose lectin (MGL) and DC-
ASGPR,38,39 which contain the Gln–Pro–Asp (QPD) sequence in the CRD, recognize
galactose-terminated or N-acetylgalactosamine (GalNAc)-terminated glycan structures. The
type II subfamily of CLRs, of which 17 members have been cloned in humans, is mainly
restricted to antigen-presenting cells (APCs) such as macrophages and DCs, whereas some
aRabinovich, G., Cobb, B., van Kooyk, Y., eds. 2012. Glycobiology of the Immune Response. Special issue, Ann. N.Y. Acad. Sci.
1253.
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of them have also been identified on NK cells or endothelial cells.40 Most C-type lectins
have internalization motifs in their cytoplasmic tail and play a role in the uptake of
glycosylated antigens that they recognize.41,42 In particular, CLRs are involved in antigen
presentation, as they take up and route antigens to the MHC class II loading compartments
to present the antigen in the context of MHC class II molecules to prime antigen-specific
CD4+ T cell responses.43 Several C-type lectins expressed on DCs have also been reported
to shuttle antigen intracellularly to the MHC class I loading compartment through a yet
uncharacterized cross-presentation route, thereby promoting antigen-specific CD8+ T cell
responses.44–47 CLRs can have inhibitory or activating domains in the cytoplasmic tail,
leading to signaling that either negatively or positively influences immune responses.37,48
This illustrates that amino acid sequences of CLRs can have profound regulatory functions
in antigen processing and presentation for instructing T cells and altering signaling cascades.
Mice also express C-type lectins, but certain members of the mouse CLR family differ
substantially from human CLRs, making the direct comparison of mouse data to a human
setting difficult. For example, DC-SIGN has various homologues in the mice, such as
SIGNR1, SIGNR3, and mDC-SIGN.49 In total, seven DC-SIGN homologues have been
identified, but none of them has the exact APC-restricted expression or glycan specificity as
human DC-SIGN. Also, for human MGL, which exhibits GalNAc specificity, two mouse
homologues have been described, MGL1 and MGL2, with glycan specificity of LeX and
GalNAc, respectively.50,51 On the other hand, some CLRs can be quite homologous
between human and mice, such as Langerin, on Langerhans cells in the skin, and Dectin-1,
which recognizes β-glucans on yeasts.52
GBPs have been shown to be involved in pathogen binding and therefore function as PRRs
through the recognition of glycans exposed on pathogens, ranging from viruses and bacteria
to yeasts and parasites.23 In particular those receptors with glycan specificity for Lewis and
mannose glycans (such as DC-SIGN) have been shown to bind a multitude of pathogens,
such as HIV-1 and other viruses, bacteria such as Mycobacterium tuberculosis and
Helicobacer pylori, helminths such as Schistosoma mansoni, and yeasts such as Candida
albicans.23,48,53,54 Glycan structures on these pathogens—high mannose, Lewis X or Lewis
Y, or LDNF—are recognized by DC-SIGN. Pathogen-binding CLRs are also internalization
receptors, by which recognition of pathogens results in the uptake of the pathogen by
APCs.55 Because CLRs play essential roles in the recognition of pathogens, they are
formally considered PRRs, similar to TLRs; however, the function of CLRs is distinct from
TLRs because the latter are not thought to internalize antigens for processing and
presentation by MHC class I or II molecules. Surprisingly, many reports also illustrate the
different signaling function that CLRs play by interfering with TLRs or Fc receptor (FcR)
triggering. In particular, CLRs may signal via Syk- or Raf-1–dependent pathways upon
interactions with specific glycans.48,56,57 CLRs are equipped with signaling motifs in their
cytoplasmic tails and/or associate with signaling complexes, although some CLRs (e.g., DC-
SIGN) may only induce gene expression in the presence of other PRRs. Upon recognition of
fungal β-glucan structures, the well-described CLR Dectin-1 triggers signaling through the
Syk tyrosine kinase and activation of ERK- and JNK-mediated cascades, which, in turn,
activate the transcription factor nuclear factor kappa B (NF-κB).48,52,58 These signaling
events are dependent on the adaptor CARD9 and are independent of TLR signaling. Other
CLRs, such as DC-SIGN, interact with mycobacterial ManLAM, and thereby promote the
production of proinflammatory cytokines, such as IL-6 and IL-12, via a Raf-1–mediated
signaling pathway. In contrast, fucose interaction with DC-SIGN initiates Raf-1–
independent signaling pathways, resulting in the induction of anti-inflammatory cytokines,
such as IL-10, and inhibition of proinflammatory cytokines, such as IL-6 and IL-12.57 This
illustrates the notion that the glycan signature of pathogens can trigger different signaling
processes, all through the same CLR.
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Most GBPs are not pathogen-restricted, as they often interact with self-glycoproteins that
have exposed mannose/fucose or GalNAc glycan structures.59 These glycans can be found
on proteins or lipids, and the multivalency of glycans can often increase the avidity to
GBPs.60 Tumor antigens commonly show an altered glycan composition that is reflected by
a shorter glycosylation backbone or by the multivalent exposure of glycan epitopes on
repeated sequences. This is well illustrated by the mucin repeated sequences in the tumor
antigen MUC-1, which shows increased binding to MGL, or by the binding of tumor-
specific carcinoembryonic antigen (CEA) to DC-SIGN.61,62 Most often, GBPs can
recognize single glycan structures; but in a few cases the protein backbone is also crucial for
specific glycans to be recognized by CLRs. As an example, DC-SIGN does not recognize
sialylated glycans, yet sialylated IgGFc is recognized by DC-SIGN and has been shown to
contribute to the anti-inflammatory activity of intravenous immunoglobulins (IVIGs),
together with the inhibitory FcR FcyRIIB, in promoting the production of the Th2-type
cytokine IL-33 and expansion of IL-4+ basophils.26
Pathogens can also display specific glycans, as exemplified by helminth glycans such as
LDNF (GalNAcβ1–4(Fucα1–3)GlcNAc-R) and LDN (GalNAcβ1–4GlcNAc-R) that can
interact with GBPs with high affinity.53 Other pathogens, such as HIV-1, display high-
mannose structures that are not particularly pathogen-specific but show high-affinity
interactions for certain GBPs, such as the C-type lectins DC-SIGN, MR, langerin, and
dendritic cell immunoreceptor (DCIR).63–65 CLRs such as DC-SIGN, MR, or MGL are
well-known to recognize endogenous glycoproteins, and thereby function as adhesion
molecules, signaling receptors, or antigen uptake mediators.66 DC-SIGN has been
demonstrated to interact with ICAM-2 and ICAM-3 to mediate cell adhesion and rolling of
DCs due to expression of Lewis Y on endothelial cells. DC-SIGN has also been reported to
interact with Lewis X (Fig. 1) and Y glycans present on Mac-1 and CEACAM-1 on
neutrophils, thereby allowing regulated adhesion between neutrophils and DCs.67 The
presence of GalNAc on CD45 expressed by effector memory CD4+ and CD8+ T cells has
been shown to interact with the C-type lectin MGL, found mainly on tolerogenic APCs, and
induce apoptosis and proliferation of these cells—demonstrating a homeostatic regulatory
role of glycans exposed on CD45.68 Furthermore, C-type lectins such as MR, Langerin, and
DC-SIGN also recognize tissue antigens, for example serum hydrolases, tissue plasminogen
activator, type I collagen, and Fc-IgG. Because MR, Langerin, and DC-SIGN have
internalization capacity, their uptake serves to control homeostatic surveillance by APCs,
such as DCs and macrophages.35
Similar to CLRs, siglecs are cell surface GBPs capable of conveying regulatory signals that
positively or negatively control immune responses. Although most siglecs are known to be
negative regulators of cell signaling, because they contain immune receptor tyrosine-based
inhibitory motifs (ITIMs), others have been shown to promote immune cell activation.69
Structurally, siglecs belong to the immunoglobulin superfamily and can be divided into two
subsets: the less-related group (25–35% identity), which includes sialoadhesin (Sn:
siglec-1), CD22 (siglec-2), and myelin-associated glycoprotein (MAG; siglec-4), and the
rapidly-evolving group of CD33-related siglecs that share high sequence similarity (50–
90%) (siglec-3, -5, -7, -8, -9, -10, -11, and -14 in humans and siglec-E, -F, -G, and -H in
mice).70 The latter GBPs are defined by their well-known carbohydrate specificity for sialic
acid-containing glycans, and for their ability to discriminate among different linkages (α2–3,
α2–6, and α2–8).71 These glycan structures can be found on immune cells, epithelial cells,
and tumor cells. Interestingly, microbes may capture sialic acid from host cells, which
prevents their immune recognition as foreign and enables infection of host target cells
through specific recognition of siglecs.71 This is clearly exemplified by Campylobacter
jejuni, Neisseria meningitides, and group B streptococci, which interact with CD33-related
siglecs.72 Unique to this lectin family, siglecs can mediate cis and trans interactions with
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sialylated glycans. Although with cis interactions the siglec is often masked by low-affinity
ligands on neighboring receptors, these linkages do not prevent trans interactions with other
cell types.69
Although some siglecs have very restricted localization patterns, others are more widely
expressed within hematopoietic cells. For example, Sn is preferentially expressed on
macrophages, CD22 on B cells, and siglec-8 on eosinophils.69 Interestingly, siglec-9 and
siglec-E are selectively expressed on human and mouse myeloid–derived DCs, respectively,
while siglec-5 and siglec-H are expressed on human and mouse plasmacytoid DCs,
respectively.69 For most CD33-related siglecs, ligand engagement results in tyrosine
phosphorylation of ITIMs by Src family tyrosine kinases and recruitment of Src homology 2
(SH2)–containing phosphatases (SHPs), such as SHP-1 and SHP-2, which control cellular
activation by attenuating tyrosine phosphorylation.73 Recent work has identified siglec-10 in
humans and siglec-G in mice as binding partners that recognize CD24 and discriminate
between pathogen-associated and danger-associated molecular partners.74 Moreover, like
CLRs, siglec-H has been identified as a specific endocytic receptor on plasmacytoid DCs
that can take up viruses and other pathogens for delivery to intracellular TLRs and,
ultimately, for induction of antiviral immunity.75 In contrast to other members of the family,
siglec-H lacks tyrosine-based signaling motifs and associates with the adaptor DAP-12 to
exert its function.75 Thus, selective targeting of individual siglecs may serve to differentially
shape immune cell signaling.
In contrast to C-type lectins and siglecs, which are mostly cell surface–associated receptors,
galectins belong to a category of soluble immunomodulatory proteins that may act either
intracellularly, by modulating signaling pathways, or extracellularly, as bioactive regulatory
mediators.76 Galectins bind to N-acetyllactosamine (Galβ1,3GlcNAc or Galβ1,4GlcNAc), a
common disaccharide found on many N- and O-linked glycans present in different cellular
counter-receptors and matricellular proteins25 (Fig. 1). Although galectins do not have the
signal sequence required for the classical secretion pathway, most of them are secreted via a
nonclassical export route that is still poorly understood.77 Traditionally, galectins are
classified into prototype galectins (galectin-1, -2, -5, -7, -10, -11, -13, -14, -15), which have
one CRD that can dimerize, tandem repeat galectins (galectin-4, -6, -8, -9 and -12), which
contain two homologous CRDs in tandem in a single polypeptide chain, and the single
member galectin-3, which is unique in that it contains a CRD connected to a non-lectin N-
terminal region that is responsible for lectin oligomerization.78 Although some galectins
have a wide tissue distribution (e.g., galectin-1 and -3), others have preferential localization,
for example, galectin-7 in skin, galectin-12 in adipose tissue, and galectin-10 in eosinophils
and regulatory T cells.77 Interestingly, galectin-3 and galectin-9 play key roles as PRRs by
discriminating Leishmania species to stimulate appropriate innate immune responses.78
Different factors can regulate the function of galectins, including (1) their dynamic
expression during the development and resolution of innate and adaptive immune responses;
(2) the programmed remodeling of cell surface glycans generated by the concerted action of
glycosyltransferases; (3) their dimerization or oligomerization status; and (4) the stability of
these proteins in oxidative or reducing microenvironments.77 Through their ability to
recognize specific glycan structures, galectins are potential soluble mediators involved in
immune cell communication, signaling, host–microbial interactions, T helper cell
homeostasis, preservation of fetomaternal tolerance, and suppression of autoimmune
pathology. In addition, galectins may contribute to the creation of immunosuppressive
microenvironments at sites of tumor growth and metastasis.25
Interestingly, accruing evidence from a number of laboratories indicates that N- and O-
glycosylation can modulate interactions of receptors and ligands themselves, thereby
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altering receptor endocytosis, clustering, and signaling. Lectins, particularly galectins, have
been shown to play critical roles in these cellular processes through binding and cross-
linking specific glycans attached to a preferred set of counter-receptors, thereby forming
supramolecular interactions or lattices that fine-tune the dynamics of receptor-ligand
interactions.12,79 This includes modulation of cytokine receptor signaling, T cell receptor
(TCR)–mediated activation at sites of immunological synapse, and B cell receptor (BCR)–
integrin signaling during B cell maturation.12 However, galectins can also bind their ligands
in a carbohydrate-independent manner, which is often the case for galectins localized in the
intracellular compartment, where ligand binding occurs predominantly via protein–protein
interactions.25
Although the in vivo roles of endogenous galectins are just now emerging, recent studies
have demonstrated distinctive immunological phenotypes in mice lacking individual
members of the family. For example, mice lacking the gene for either galectin-1 or
galectin-9 show increased Th1 and Th17 responses and augmented inflammatory
responses,80–82 whereas mice deficient in galectin-3 exhibit reduced inflammation in mouse
models of multiple sclerosis and arthritis.83,84 Thus, in spite of protein sequence similarities,
overlapping distribution, and functional redundancy, individual members of the galectin
family may play distinct roles in the control of immune cell homeostasis. Moreover,
different lectin families may overlap, synergize, and/or counter-regulate the effect of each
other through recognition of a similar set of glycan ligands. Given their multifunctional
properties and versatility, GBPs, including CLRs, siglecs, and galectins, are increasingly
recognized as molecular targets for innovative drug discovery in immune-mediated
disorders.
Glycobiology of autoimmunity and chronic inflammation
In spite of compelling evidence of the role of glycosylation in pathogen recognition, our
awareness of the impact of lectin–glycan interactions in the control of immune tolerance,
autoimmunity, and chronic inflammation is relatively new. These emerging data are based
on pioneering observations demonstrating programmed remodeling of cell surface glycans
in the transition from normal to inflamed tissues.85 These changes affect emigration and
trafficking of immune cells to sites of inflammation, as demonstrated for selectins that bind
to sialylated and fucosylated epitopes (e.g., sLex) often found in sulphated form on glycans
present on most leukocytes and endothelial cells.86 Thus, inhibition of selectins and glycans
during leukocyte–endothelium interactions has been proposed as an attractive target for anti-
inflammatory therapy.
However, glycosylation can control inflammation and autoimmunity through modulation of
other homeostatic checkpoints. In fact, in several inflammatory autoimmune diseases, such
as systemic lupus erythematosus and rheumatoid arthritis, effector T cells express altered
cell surface glycans, especially those exposing terminal GalNAc and Gal-β(1–4)-GlcNAc
structures.87 For example, MGL and galectin interactions with these structures thereby
downregulate TCR signaling and alter CD45 phosphatase activity.18,39,68 In addition,
glycosylation can alter the threshold of TCR activation, which can have profound effects on
T cell function during adaptive immunity and autoimmune diseases. The GnT5
glycosyltransferase, encoded by the mannoside acetylglucosaminyl transferase 5 (Mgat5)
gene, initiates formation of the β1–6-N-glycan-branch structure on various glycoproteins,
including the TCR. This N-glycan branch typically includes N-acetyllactosamine (LacNAc;
Fig. 1) disaccharide repeats that serve as ligands for galectins. T cells lacking GnT5 have a
decreased threshold for T cell activation, and GnT5-deficient mice have increased delayed-
type hypersensitivity responses and increased susceptibility to autoimmune diseases,
including experimental autoimmune encephalomyelitis (EAE), glomerulonephritis, and
Rabinovich et al. Page 8
Ann N Y Acad Sci. Author manuscript; available in PMC 2014 January 08.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
immune complex deposition.18 Interestingly, treatment with high doses of GlcNAc was
shown to increase GnT5-mediated N-glycan branching and inhibited TCR activation in
autoimmune models of EAE and diabetes.88
Although these studies highlight the relevance of glycosylation in the control of adaptive
immunity and the development of autoimmune diseases, other studies have been
instrumental to understanding the contribution of innate immune mechanisms to
autoimmune and inflammatory settings. Deficiency in α-mannosidase-II (αM-II), which
results in diminished complex-type N-glycan branching, has been shown to induce an
autoimmune disease in mice similar to human systemic lupus erythematosus.89 This effect
was independent of the adaptive immune system and was linked to chronic activation of
innate immune components. The authors proposed a mechanism by which the exposure of
cryptic N-glycans under αM-II deficiency (i.e., mannose-dependent ligands) results in
recognition by endogenous lectins (including MR) and aberrant activation of innate immune
responses in the absence of infection, thus leading to the development of lupus-like
autoimmune disease.89 Thus, selective targeting of glycan-modifying enzymes, early or late
during N-complex glycan branching, can result in aberrant activation of innate or adaptive
immune responses.
However, it is not only N-glycans that influence the development and resolution of
autoimmune response. In patients with IgA nephropathy, for example, O-glycans attached to
IgA are truncated to expose GlcNAc, which correlates with antibody deposition in the
inflamed kidney;90 this suggests that differential glycosylation of immunoglobulins
critically regulates their biological functions. A striking example of this is the presence of
α2,6 sialic acid in the Fc region of IgG, which determines the anti-inflammatory function of
IVIGs in several autoimmune diseases.26
Antibodies specific for glycans have been found in different settings. For example, because
humans lack the enzyme that converts N-acetylneuraminic acid (NeuAc) to N-
glycolylneuraminic acid (NeuGc), incorporation of NeuGc in the diet can lead to the
generation of antibodies against NeuGc.91 In addition, antibodies specific for particular
glycans have also been found in the human Tn syndrome, which is characterized by
thrombocytopenia and leukocytopenia and caused by a mutation in the COSMC gene
encoding a chaperone required for β1,3 galactosyltransferase (T-synthase) activity required
for O-glycan biosynthesis.92
The biological roles for the different repertoires of cell surface glycans found on different
immune cell types are just emerging. For example, α2,6-linked sialic acid is selectively
upregulated on the surface of Th2 but not Th1 and Th17 effector cells, and this difference
determines the susceptibility of these T cell subsets to the GBP galectin-1.80 Accordingly,
galectin-1–deficient (Lgals1−/−) mice develop more severe autoimmune manifestations
during EAE due to selective expansion of antigen-specific Th1 and Th17 cells and to
increased immunogenicity of DCs.80,93 Therapeutic administration of recombinant
galectin-1 has been shown to restore tolerance and suppress chronic inflammation in several
experimental models of autoimmunity (arthritis, uveitis, EAE, hepatitis, diabetes, and
inflammatory bowel disease); to prevent fetal loss; and to attenuate graft-versus-host disease
by suppressing Th1 and Th17 responses, by expanding regulatory T cell populations, and by
fueling tolerogenic DC circuits (reviewed in Ref. 76). These effects were also observed
following administration of the tandem-repeat galectin-9, which suppresses harmful
autoimmune responses through its ability to bind the Tim-3 glycoreceptor.81
C-type lectins can also play important roles in the modulation of inflammatory and
autoimmune diseases. In vivo targeting of a mannosylated encephalitogenic peptide has been
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shown to inhibit the onset of EAE, most likely by targeting the mannose receptor on
immature DCs.94 Similarly, oral administration of mannose-enriched antigens can induce
oral tolerance and favor the generation of IL-10–producing regulatory T (Tr1) cells through
mechanisms involving the CLR SIGNR1 expressed on lamina propria DCs.95 Moreover,
siglec-2 (CD22) delivers inhibitory signals to B cells, and siglec-G/CD22 double knockout
mice spontaneously develop B cell–dependent autoimmunity characterized by the presence
of anti-DNA and antinuclear autoantibodies.96 These data suggest that different GBPs may
amplify or silence tolerogenic circuits within DC, T cell, or B cell compartments.
Glycobiology of tumor immunity
Changes in the glycosylation status of certain tumor-associated antigens (TAAs) are often
accompanied by onco-transformation. Such TAAs include the CEA and MUC1.62,63 Both
antigens are expressed on cells of normal colonic mucosa and the epithelium. Changes in
glycosylation include increased expression of the Lewis blood group family of antigens,
particularly Lex and Ley, that are often associated with poor prognosis of the tumor. How
these posttranslational modifications contribute to tumor cell dissemination and disease
severity is not fully understood. However, recent findings demonstrate that DCs recognize
these aberrantly glycosylated structures on CEA or MUC1 through CLRs, such as DC-SIGN
and MGL, respectively, while these CLRs do not interact with normal CEA or MUC1 from
colon tissue.97
Several studies have demonstrated that specific targeting of antigens to CLRs can result in
more robust antitumor responses. An elegant study demonstrated that in vivo targeting of
CLRs in the mouse can induce antigen-specific autoimmune responses when the antigen is
coupled to a DEC-205–specific antibody.98 In contrast, when the antigen coupled to
DEC-205-Ab is simultaneously combined with a strong DC activator, such as a TLR
agonist, a strong antigen-specific immune activation is induced that results in potentiation of
antitumor responses and, ultimately, eradication of the tumor. Moreover, other CLRs have
also been used for targeting purposes resulting in strong induction of immunity.99–101
CLEC9A is a CLR predominantly expressed on a subset of DCs in human and mice that
functions to promote phagocytosis of dead cells for MHC class I–dependent cross-
presentation and stimulation of CD8+ T cell responses. The precise ligand recognized by
CLEC9A on dead cells has not yet been identified, and it is under debate whether CLEC9A
ultimately recognizes glycan structures or protein frameworks. The targeting of antigen to
CLEC9A, using antibody–antigen conjugates, has led to the efficient endocytosis of antigen
and to enhanced CD4+ and CD8+ T cell proliferation and more robust antibody responses.
Furthermore, targeting of CLEC9A in cancer cells in mouse models has been shown to
heighten T cell–mediated tumor rejection.47,102 In addition, another strategy to target
antigen to CLRs on DCs involves using natural ligands (glycan structures) to modify
antigen.103 The use of glycans for in vivo DC-targeting purposes has advantages over CLR-
specific antibodies because glycans, which are nonimmunogenic and of self-origin, can be
produced synthetically to large scale using simple chemistry.104 In contrast, the production
of humanized antibodies is expensive, and such antibodies can be immunogenic in patients.
Furthermore, antibodies themselves are highly glycosylated, a property that is currently
being capitalized on to increase or decrease their therapeutic potential in vivo.
Modification of the melanoma antigen gp100 with high mannose has been demonstrated to
enhance both gp100-specific CD4+ and CD8+ T cell responses, because high-mannose
structures target DC-SIGN on DCs and this leads to enhanced endosomal-dependent antigen
presentation.55 Ovalbumin (OVA) modified with fucose-containing Lewisb structures not
only improved targeting of OVA to DC-SIGN, as shown by enhanced antigen uptake by
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DCs from DC-SIGN transgenic mice, but also increased cross-presentation to OVA-specific
CD8+ and CD4+ T cells.44 Moreover, two other MR-specific ligands, sulfo LewisA or
GlcNAc, significantly enhanced targeting of OVA to the MR when they were ligated to
OVA, thereby increasing cross-presentation of OVA to OT-I (OVA-specific) T cells in
vitro.100 Interestingly, in both studies using the natural ligands to target antigen to CLR,
cross-presentation was increased in the absence of DC maturation signals. Improvement in
CD4+ and CD8+ T cell priming has been demonstrated not only by modification of antigens
with glycans; glycosylated nanoparticles have also been designed that specifically target
DCs to improve antigen-specific immune responses. In addition, CLRs are currently being
used to enhance delivery of several vaccines to DCs, as well as to improve CD4+ and CD8+
T cell priming, due to the high efficacy of CLRs to promote antigen processing in these
APCs.
Emerging evidence indicates that tumors may exploit lectin–glycan interactions to evade
immune responses.105 Galectin-1 secreted by tumor cells contributes to the
immunosuppressive potential of different tumor types, including melanoma,106,107
Hodgkin’s lymphoma,108 lung carcinoma,109,110 pancreatic carcinoma,111 and
neuroblastoma,112 by selectively modulating T cell and DC compartments. The mechanisms
underlying this immunoregulatory effect involve a bias toward a Th2-dominant cytokine
profile and activation of tolerogenic circuits mediated by IL-27–producing DCs and IL-10–
producing type 1 T regulatory (Tr1) cells.93,110 Moreover, overexpression of galectin-9
results in increased frequency of CD11b+Ly-6G+ granulocytic myeloid suppressor cells and
inhibition of antitumor responses,113 while the presence of galectin-3 appears to control the
anergic state of T cells.114 Thus, selective inhibition of individual members of the galectin
family may contribute to circumventing immunosuppression at sites of tumor growth by
targeting distinct immunoevasive programs.
Recent work has demonstrated a novel glycosylation-dependent mechanism of tumor-
immune escape. Bladder tumor cells overexpressing the core-2 β-1, 6-N-
acetylglucosaminyltransferase (GCNT1 encoded by C2GnT), which is responsible for
elongating core-2 O-glycans (i.e., O-glycans containing a GlcNAc branch connected to
GalNAc; Fig. 1), are highly metastatic due to their ability to evade NK cell immunity. The
recent data suggest that interactions between poly-LacNAc residues present on core-2 O-
glycans of tumor-associated MHC class I–related chain A (MICA) and galectin-3 reduced
the affinity of MICA for the activating NK receptor NKG2D, thereby impairing NK cell
activation and antitumor activity.115 Similarly, expression of the ganglioside GD3 by tumor
cells can also alter NK cell cytotoxicity via siglec-7–dependent mechanisms.116 Moreover,
mucins derived from human cancer patients can control the immunogenicity of DCs through
mechanisms involving siglec-9.117
Collectively, these data indicate that, in addition to differential gene and protein expression
profiles, the lectin repertoire, as well as the cellular glycosylation signatures prevailing in
the tumor microenvironment, may provide distinctive cellular codes that influence immune
cell fate and cancer progression.
Conclusions
In this issue of Annals of the New York Academy of Sciences, reviews are presented on the
multifaceted and often unexpected roles played by carbohydrates within the immune system.
These include how sialic acids control immunity; the impact of glycans and glycosylation on
cancer, autoimmunity, and lymphocyte development; and the role of carbohydrates on host
and microbe during infection. This brief introduction highlights some of the best-
characterized areas of glycan-focused immunology research, with the goal of illustrating the
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fact that carbohydrates are as integral to immune pathways as are proteins and lipids. The
field of glycoimmunology is just beginning to find solid grounding through improved and
more accessible carbohydrate-specific analytical tools. We hope the reviews presented in
this special issue will encourage the immunology community to take notice of myriad
unanswered questions on how carbohydrates influence immune responses. Deep
investigation of these questions will surely lead to a greater understanding of the function of
the immune system, and eventually of biology as a whole.
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Figure 1.
Schematic of the N- and O-linked glycosylation pathway in mammals. (Top) The asparagine
(N)-linked pathway begins in the endoplasmic reticulum (ER), where OST
(oligosaccharyltransferase) moves the core N-glycan from the dolichol precursor to an
asparagine residue with the N-X-S/T consensus sequence. This structure is trimmed by
glucosidases (Glc I and Glc II) within the ER, which assist in the folding quality control
system mediated by the calnexin/calreticulin pathway. Once released from this quality
control, the nascent glycoprotein traffics to the Golgi apparatus where further trimming
occurs initially, which is then followed by the creation of significant diversity through
addition of other saccharides by a variety of transferases (“T” in the abbreviations) in a
nontemplate-driven process. Another key addition are 2,3-linked and 2,6-linked terminal
sialic acids, which are critical for a number of biological functions. Finally, the LacNAc
disaccharide unit (N-acetyllactosamine) is a key recognition site for a number of glycan-
binding molecules, including some of the galectin family. (Bottom) The serine/threonine
(O)-linked glycosylation pathway is distinct from the N-linked pathway in a number of
ways. The nature of the linkage and the enzymes involved are separate, and the resulting
structures are quite divergent, although some similarities exist, such as the presence of the
LacNAc unit. The O-linked glycans are broken down into core subgroups and carry names
like “Tn antigen” and “Sialyl-Lewisx” that are common in the literature. These have been
labeled for reference.
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Figure 2.
Lectin-glycan interactions in innate immunity: Discrimination of non-self, altered-self, and
self by antigen-presenting cells (APCs). GBPs (e.g., DC-SIGN, Dectin-1, siglec-1,
galectin-3 (Gal-3), galectin-9 (Gal-9)) can function as pattern recognition receptors (PRR)
through the recognition of non-self glycans exposed on different pathogens, including
viruses, bacteria, yeasts, and parasites. In particular those CLRs with glycan specificity for
Lewis and mannose glycans (such as DC-SIGN) have been shown to bind a multitude of
pathogens such as HIV-1 and other viruses, bacteria such as Mycobacterium tuberculosis
and Helicobacer pylori, helminths such as Schistosoma mansoni, and yeasts such as
Candida albicans. On the other hand, Gal-3 and Gal-9 play key roles as soluble PPRs by
discriminating Leishmania species. Also, CLRs (e.g., MGL, DC-SIGN) can detect changes
in glycosylation of certain tumor-associated antigens, such as the carcinoma embryonic
antigen (CEA) and MUC1 occurring during onco-transformation and tumor progression.
These changes include increased expression of the Lewis blood group family of antigens,
particularly Lex, and Ley, that are often associated with poor prognosis of the tumor. This
recognition allows antigen internalization, presentation to CD4+ T cells, cross-presentation
to CD8+ T cells, and potentiation of antitumor immunity, although in some cases these
interactions can also lead to inhibition of T cell responses. In addition, GBPs may play
important roles in self-recognition in a variety of cellular processes, including (among
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others) cell adhesion (DC-SIGN-ICAM1/3 interactions), T cell signaling (MGL interactions
with GalNAc-expressing CD45 glycoforms), discrimination of danger signals (interactions
among siglec-G, CD24, and the HMGB1 alarmin), and modulation of immunogenic or
tolerogenic APC programs (e.g., interactions between galectins and APC glycoproteins,
such as Tim-3 and CD43).
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